Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation

Background: Lung cancer is the second most diagnosed cancer in the UK. Over 70% of lung cancers are non-small cell lung cancers (NSCLCs). Patients with stage III or IV NSCLC may be offered treatment to improve survival, disease control and quality of life. One-third of these patients receive further...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Janette Greenhalgh, Adrian Bagust, Angela Boland, Kerry Dwan, Sophie Beale, Juliet Hockenhull, Christine Proudlove, Yenal Dundar, Marty Richardson, Rumona Dickson, Anna Mullard, Ernie Marshall
Formato: Artigo
Idioma:Inglês
Publicado em: NIHR Journals Library 2015-06-01
Colecção:Health Technology Assessment
Assuntos:
erlotinib
gefitinib
non-small cell lung cancer
systematic review
epidermal growth factor mutation
docetaxel
Acesso em linha:https://doi.org/10.3310/hta19470
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados